NGM · Drug Manufacturers - Specialty & Generic
INCR (INCR) Stock
$0.90
-6.52%
NGM: INCR
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
GlobeNewswire · Jun 22, 2026
InterCure Starts Review of US Medical Cannabis Opportunities; Completes Initial Closing of Botanico Acquisition
MT Newswires · Jun 15, 2026
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
GlobeNewswire · Jun 15, 2026
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
GlobeNewswire · Apr 30, 2026
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About INCR
INCR is led by CEO Alexander Rabinovich, employs 320 people, headquartered in IL, publicly traded since 2019.
INCR stock trades at $0.90 with a market capitalization of $51.61M. The stock is valued at a price-to-earnings (P/E) ratio of -1.37, price-to-book of 0.12, price-to-sales of 0.74. Over the past 52 weeks the stock has ranged between $0.68 and $1.77, and currently trades 49.2% below its 52-week high.
On profitability, INCR generates a return on equity (ROE) of -9.07%, return on capital employed of 1.76%, an operating margin of 2.59%, a net profit margin of -19.47%.